id_paper,id_group,id_proc,paper_first_author,paper_year,paper_journal,exposure,outcome,pop_group_exposed,pop_group_unexposed,recruitment_period,dp_period,country,location,urban_rural,geographic_scope,study_design,recruitment_setting_controls,refusal_rate_percent,missing_data_percent,hiv_coinfection,other_infection,study_link,control_type,exposure_ascertainment,outcome_ascertainment,vaccine_regimen,full_vaccine_schedule,age_at_first_dose_years,vaccine_efficacy_calculation,adjusted_confounders,adjusted_for_clustering,study_details,age_min_years,age_max_years,age_mean_years,age_sd_years,age_median_years,age_iqr_years,age_distribution_years,sex,proportion_male,hbsag_positive_prop_vaccinated,hbsag_positive_prop_unvaccinated,vaccine_efficacy,vaccine_efficacy_ci_lower,vaccine_efficacy_ci_upper,sample_size,dp_details,processing_notes
V1,x,x,Peto,2014,BMC Infectious Diseases,Infant vaccine,Current infection,Vaccinated GHIS participants,Unvaccinated GHIS participants,"1978, 1989",2007-2008,Gambia,Central River Region (40 villages in 2 areas),Mixed,National,Cohort (retrospective)/randomised trial,Community-based,NR,72% of 2670,NR,NR (HCV prevalence was 0.5% of 2670),GHIS,Concurrent,GHIS database linkage,HBsAg at one time point,"Up to 4 doses of 10 microgram plasma-derived vaccine, the first as soon as possible after birth and the others scheduled at 2, 4 and 9 months of age",Yes,0-0.17,OR,"Yes - study area, age, sex, urban/rural",No,the regions for sampling were chosen as 2 early adopters of HBV vaccination - since 1987 -and 2 late adopters - since 1989. Unvaccinated participants were from the same area as vaccinees.,17,21,NR,NA,NR,NR,NR,Mixed,NR,0.008,0.124,0.94,0.77,0.99,667,"192 cases, 475 controls",NA
V3,x,x,Fortuin,1993,The Lancet,Infant vaccine,Chronic infection,Vaccinated GHIS participants,Unvaccinated GHIS participants,1986-1989,1990-1991,Gambia,"Nationwide (Western region north and south bank, central region, Eastern region)",Mixed,National,Cohort/randomised trial,Community-based,NR,31% of 1041,NR,NR,GHIS,Concurrent,"Follow-up of vaccinees, GHIS database linkage",HBsAg at 2 time points,"Up to 4 doses of 10 microgram plasma-derived vaccine, the first as soon as possible after birth and the others scheduled at 2, 4 and 9 months of age",NR,0-0.17,RR,No,No,Vaccinees are the group 1 cohort. Missing data represents loss to follow-up in the group 1 cohort.,3,4,4,NR,NR,NR,NR,Mixed,NR,0.006,0.13,0.94,0.84,0.98,1536,"720 cases, 816 controls",NA
V4,x,x,Viviani,1999,Vaccine,Infant vaccine,Chronic infection,Vaccinated GHIS participants,Unvaccinated GHIS participants,1986-1989,1995-1996,Gambia,"Nationwide (Western region north and south bank, central region, Eastern region)",Mixed,National,Cohort/randomised trial,Community-based,NR,35% of 1041,NR,NR,GHIS,Concurrent,"Follow-up of vaccinees, GHIS database linkage",HBsAg at 2 time points,"Up to 4 doses of 10 microgram plasma-derived vaccine, the first as soon as possible after birth and the others scheduled at 2, 4 and 9 months of age",NR,0-0.17,RR,"Yes - geographical zone, sex",NR,Vaccinees are the group 1 cohort. Missing data represents loss to follow-up in the group 1 cohort.,9,9,9,NR,9,NA,NR,Mixed,NR,0.005,0.12,0.94,0.84,0.98,1498,"675 cases, 823 controls",NA
V5,x,x,Van der Sande,2007,PLOS One,Infant vaccine,Chronic infection,Vaccinated GHIS participants,Unvaccinated GHIS participants,1989,2004,Gambia,"Banjul, Serekunda, Brufut, Banjulunding, Sukuta",NR,National,Cohort (retrospective)/randomised trial,Community-based,NR,42% of 3709,NR,NR,GHIS,Concurrent,GHIS database linkage,HBsAg at 2 time points,"Up to 4 doses of 10 microgram plasma-derived vaccine, the first as soon as possible after birth and the others scheduled at 2, 4 and 9 months of age",Yes,0-0.17,RR,No,NR,"Study location was the catchment areas where vaccination started only in 1989. Also reports vaccine efficacy of partial regimen (1-2 doses). Mean age in controls was 15.5 (SD 0.3).  ""It is plausible that natural mixing between geographical areas could have resulted in some indirect protection of the unvaccinated.""",14,16,14.9,0.4,NR,NR,NR,Mixed,0.45,0.004,0.132,0.966,0.915,1,916,"492 cases, 424 controls",NA
V12,x,x,Mendy,2013,PLoS ONE,Infant vaccine,Chronic infection,Vaccinated Keneba-Manduar trial participants,Seronegatives in Keneba-Manduar baseline recruitment survey 1984,1984-2008,2008,Gambia,"Keneba, Manduar",Rural,Sub-national,Cohort/randomised trial,Community-based,7.8% of 1508,7.5% of 1508,NR,NR,KM vaccine cohort,Historical,"Follow-up, database linkage",HBsAg at 2 time points,"in 1984, 3 doses at 2 month intervals for 0-4 year old. From 1985, up to 4 doses at 1, 2, 4 and 9 months. 2003-2009: 3 doses",NR,0.08-4 (majority within 1 year),RR,No,NR,"missing data represents loss to follow-up in the Whittle cohort. Five children who became infected during the initial primary vaccination program in 1984 were excluded from analyses of vaccine efficacy. For historical control prevalence in 1984, prevalence in 15–19 year olds from the 1984 survey was used as a baseline for all adults as it remained stable in the population from age 15 onwards.",1,28,NR,NA,NR,NR,NR,Mixed,NR,0.011,0.198,0.951,0.915,0.971,2175,"1243 cases, 932 controls. Vaccine efficacy against chronic infection did not vary significantly between villages or by age group",NA
